In vivo evaluation of pH-sensitive polymeric microparticles for site specific drug delivery to the small intestine and colon by Kendall, RA et al.
 CS-1:CRS_2006_Kendall.docMurdan 
In vivo evaluation of pH-sensitive polymeric microparticles for site specific drug delivery to the 
small intestine and colon 
 
Richard A. Kendall, Sudaxshina Murdan, Abdul W. Basit
 
sudax.murdan@pharmacy.ac.uk 
The School of Pharmacy, University of London, 29-39 Brunswick Square, London, WC1N 1AX, U.K. 
 
 
ABSTRACT SUMMARY 
     A novel emulsification/solvent evaporation 
process was developed to formulate prednisolone-
loaded Eudragit L and S microparticles as drug 
delivery vehicles to target different regions of the 
gastrointestinal tract.  Microparticles were 
characterised in vitro and in vivo.  This is the first 
report of drug absorption form orally administered 
Eudragit L and S microparticles. 
 
INTRODUCTION 
     Delayed release oral dosage forms are designed 
to target either the small intestine (for gastric irritant 
or labile molecules) or the colon (for the treatment 
of localised disorders or delivery of peptides and 
proteins).  The most commonly used method for 
targeting these regions is to exploit the increasing 
luminal pH from stomach to colon by applying a 
pH-sensitive film coating to a core dosage form. The 
film coating polymer is expected to ionise and 
dissolve above a threshold pH specific to either the 
duodenum (pH 5-6) or colonic region (pH 7-7.5). 
 
Unfortunately, as the application of pH-sensitive 
coatings generally renders the dosage form non-
disintegrating in the stomach, gastric emptying 
becomes delayed and variable from both tablets 
(Khosla et al., 1989) and pellets (Clarke et al., 1993), 
making the onset of drug action highly 
unpredictable.  Furthermore, pharmacoscintigraphic 
studies have shown a lag time of 1-1.5 hours post 
gastric emptying before enteric coated dosage forms 
disintegrate (Ebel et al., 1993; Wilding et al., 1993), 
which further impacts onset of action and drug 
bioavailability.  Due to the limited fluid content in 
the colonic region, pH-sensitive coating dissolution 
may be further retarded, and tablets intended to 
deliver drug to the colonic region have been 
observed, on occasion, to be voided intact. 
 
The aim of this research was to formulate pH-
sensitive microparticles for small intestinal or 
colonic delivery, which may suspend in the stomach 
contents therefore emptying rapidly and 
reproducibly.  The large surface area of the pH-
sensitive microparticles should facilitate rapid drug 
release above the threshold pH of the pH-sensitive 
polymer.  The in vivo performance of the pH-
sensitive microparticles was tested in fed rat, given 
the similarities between rat and man gastrointestinal 
(GI) transit times and pH. 
 
EXPERIMENTAL METHODS 
     A novel but simple emulsification/solvent 
evaporation method was developed to produce 
Eudragit L (soluble pH>6) and S (soluble pH>7) 
prednisolone-loaded microparticles (5:1 
polymer:drug), for small intestinal and colonic drug 
delivery, respectively. Drug encapsulation efficiency 
was calculated.  Microparticles were characterised 
by SEM, particle size analysis (Malvern 
Mastersizer), and X-ray diffraction (XRD).  In-vitro 
dissolution experiments were carried out using USP 
II dissolution apparatus using a pH-change method, 
simulating gastric to small intestinal and colonic 
conditions.  Eudragit L and S microparticles and 
micronized prednisolone (control, crystalline drug 
substance, 5µm particle size) suspensions were 
administered to rats by oral gavage (2ml, 200mg/kg 
prednisolone.  Plasma samples were collected by tail 
vein sampling at 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 
hours post dose, and the plasma was assayed for 
prednisolone content by HPLC-MS/MS. 
 
RESULTS AND DISCUSSION 
     Prednisolone encapsulation efficiency was ~90% 
for both polymers.  SEM showed microparticles to 
exhibit excellent morphology, being spherical, non-
aggregated and non-porous (Fig. 1). 
 
 
 
 
 
 
 
  
Figure 1:  SEM image of Eudragit L100 (left) and S100 
(right) microspheres (bar is 100 µm) 
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Median microparticle size was <50µm, with a 
narrow size distribution, for both polymers.  XRD 
revealed that encapsulated drug was in the 
amorphous form.  In vitro, Eudragit L and S 
formulations displayed pH-responsive release, 
leaking a negligible amount of drug after 2 hour 
incubation in acid, and releasing all the drug rapidly 
(within 5 minutes) at small intestinal and colonic 
pH, respectively.   
 
The in vivo absorption profiles for the two test 
formulations and the control and summary of 
pharmacokinetic data are shown in Figures 2 and 
Table 1 below. 
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Figure 2:  Mean (±SEM) plasma concentration-time 
profiles for the three test formulations 
 
Formulation AUC (ng.h/mL) Cmax (ng/mL) Tmax (min) 
Susp. 15372 (±2377) 4152 (±829) 102 (±45) 
Eud L 20435(±18377) 8704 (±8765) 48 (±15) 
Eud S 5414 (±1570) 1376 (±444) 72 (±24) 
Figure 3:  Summary of pharmacokinetic parameters for 
the three test formulations 
 
Prednisolone absorption from Eudragit L 
microparticles was more rapid than from the control 
suspension (Table 1).  Relative bioavailability was 
also increased by one third compared to 
prednisolone suspension.  This is likely to be due to 
the rapid increase in pH from stomach to duodenum 
(from 4.5 to 6.9) in the fed rat (Ward and Coates, 
1987), which led to the rapid dissolution of the 
Eudragit L matrix (threshold pH = 6) and rapid 
release of entrapped prednisolone in a pre-
solubilised (amorphous) form.  Prednisolone was 
therefore available for rapid absorption from the 
proximal small intestine, which is the optimal site 
for the absorption of most drugs. 
 
In contrast, prednisolone absorption from Eudragit S 
microparticles was more sustained.  The lower 
absorption is due in part to the GI physiology of the 
rat, where pH above 7 (threshold pH for Eudragit S) 
only occurs in the ileal region, where fluid volume is 
also limited.  The luminal contents of the rat ileal 
region represent a far from ideal environment for 
dissolution of Eudragit S microparticles, and this 
results in a relative reduced bioavailability compared 
to the control suspension whose dissolution was 
aided by the small particle size and which occurred 
along the whole length of the GI tract.  Furthermore, 
absorption of prednisolone in the ileal region is less 
than half as efficient as from the duodenum due to 
the presence of intestinal P-glycoprotein in this 
region (Nakayama et al., (1999). Prednisolone may 
not have been the ideal model drug to test absorption 
in the lower ileum.  It is interesting to note, however, 
that although the level of prednisolone absorption 
was low for the Eudragit S microparticles, Cmax 
occurred more rapidly than from the control 
suspension.  This is probably due to release of 
amorphous prednisolone located near to the surface 
of the microparticle in the upper small intestine, 
where absorption of prednisolone is favoured. 
 
CONCLUSION 
     A novel yet simple method was developed for the 
production of Eudragit L and S microparticles, for 
small intestinal and colonic delivery.  The 
microparticles are of a size that may facilitate rapid 
gastric emptying and less variable GI transit than 
conventional delayed release dosage forms.  In vivo 
experiments in rats suggest that Eudragit L 
microparticles released a model drug, prednisolone, 
rapidly in the proximal small intestine, hastening the 
onset of drug action and improving bioavailability.  
Enhancement of bioavailability is one of the major 
challenges faced in the field of biopharmaceutics, 
given the ever increasing number of poorly soluble, 
and often basic, compounds currently in 
development.  Prednisolone absorption from 
Eudragit S microparticles was lower than anticipated 
considering the similarity of human and rat GI pH, 
but a result of low fluid volume in the rat GI tract 
which hinders dissolution and the diminished 
absorption in the lower small intestine.  The rat 
pharmacokinetic data provides the proof of concept 
data required for forthcoming studies in man. 
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